TITLE:
Metastatic Small Cell Neuroendocrine Carcinoma of the Bladder: Case Report and Literature Review
AUTHORS:
Abir Oufrid, Basma Aabboub, Lamiae Amaadour, Karima Oualla, Zineb Benbrahim, Samia Arifi, Nawfel Mellas
KEYWORDS:
Bladder, Neuroendocrine Carcinoma, Small Cell, Metastases, Chemotherapy
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.17 No.1,
December
30,
2025
ABSTRACT: Background: Small cell neuroendocrine carcinoma of the bladder (SCNECB) is a rare entity, accounting for less than 1% of bladder tumors. It progresses rapidly and has a poor prognosis. Case Presentation: We report the case of a 62-year-old man, a chronic smoker, admitted for gross hematuria that had been developing for a month. An abdominal-pelvic CT scan revealed an infiltrating bladder mass associated with liver metastases. RTUV confirmed the diagnosis of small cell neuroendocrine carcinoma through immunohistochemistry: chromogranin A, synaptophysin, and CD56 positive, Ki-67 at 80%. The patient received six cycles of cisplatin-etoposide, with an initial partial response. The disease then progressed rapidly, leading to the patient’s death eight months after diagnosis. Conclusion: This case illustrates the early metastatic presentation and rapid progression of small cell neuroendocrine carcinoma of the bladder. Despite platinum-based chemotherapy, the prognosis remains poor, especially in resource-limited countries.